INBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Integrated Biopharma has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Integrated Biopharma's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of Integrated Biopharma was 8. The lowest was 2. And the median was 6.
The historical data trend for Integrated Biopharma's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial |
![]() |
![]() |
6.00 | 8.00 | 5.00 | 4.00 | 5.00 |
Integrated Biopharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Piotroski F-Score | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.00 | 4.00 | 5.00 | 6.00 | 8.00 |
For the Packaged Foods subindustry, Integrated Biopharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Dec24) TTM: | Last Year (Dec23) TTM: |
Net Income was 0.285 + 0.268 + 0.259 + 0.116 = $0.93 Mil. Cash Flow from Operations was 1.643 + -0.186 + 0.657 + 0.201 = $2.32 Mil. Revenue was 13.147 + 12.746 + 13.617 + 12.614 = $52.12 Mil. Gross Profit was 1.248 + 1.284 + 1.371 + 1.171 = $5.07 Mil. Average Total Assets from the begining of this year (Dec23) to the end of this year (Dec24) was (25.721 + 26.942 + 26.207 + 26.183 + 25.661) / 5 = $26.1428 Mil. Total Assets at the begining of this year (Dec23) was $25.72 Mil. Long-Term Debt & Capital Lease Obligation was $0.36 Mil. Total Current Assets was $18.15 Mil. Total Current Liabilities was $5.58 Mil. |
Net Income was 0.016 + 0.04 + -0.059 + -0.382 = $-0.39 Mil. Revenue was 13.098 + 12.994 + 12.915 + 11.509 = $50.52 Mil. Gross Profit was 1.008 + 0.986 + 0.832 + 0.52 = $3.35 Mil. Average Total Assets from the begining of last year (Dec22) to the end of last year (Dec23) was (26.052 + 26.88 + 25.431 + 26.642 + 25.721) / 5 = $26.1452 Mil. Total Assets at the begining of last year (Dec22) was $26.05 Mil. Long-Term Debt & Capital Lease Obligation was $1.32 Mil. Total Current Assets was $17.07 Mil. Total Current Liabilities was $5.83 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Integrated Biopharma's current Net Income (TTM) was 0.93.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Integrated Biopharma's current Cash Flow from Operations (TTM) was 2.32.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Dec23) |
= | 0.928 | / | 25.721 | |
= | 0.03607947 |
ROA (Last Year) | = | Net Income | / | Total Assets (Dec22) |
= | -0.385 | / | 26.052 | |
= | -0.01477814 |
Integrated Biopharma's return on assets of this year was 0.03607947. Integrated Biopharma's return on assets of last year was -0.01477814.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Integrated Biopharma's current Net Income (TTM) was 0.93. Integrated Biopharma's current Cash Flow from Operations (TTM) was 2.32.
==> 2.32 > 0.93 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Dec24) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Dec23 to Dec24 |
= | 0.359 | / | 26.1428 | |
= | 0.01373227 |
Gearing (Last Year: Dec23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Dec22 to Dec23 |
= | 1.322 | / | 26.1452 | |
= | 0.05056377 |
Integrated Biopharma's gearing of this year was 0.01373227. Integrated Biopharma's gearing of last year was 0.05056377.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Dec24) | = | Total Current Assets | / | Total Current Liabilities |
= | 18.153 | / | 5.575 | |
= | 3.2561435 |
Current Ratio (Last Year: Dec23) | = | Total Current Assets | / | Total Current Liabilities |
= | 17.065 | / | 5.833 | |
= | 2.92559575 |
Integrated Biopharma's current ratio of this year was 3.2561435. Integrated Biopharma's current ratio of last year was 2.92559575.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Integrated Biopharma's number of shares in issue this year was 31.303. Integrated Biopharma's number of shares in issue last year was 30.1.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 5.074 | / | 52.124 | |
= | 0.09734479 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 3.346 | / | 50.516 | |
= | 0.06623644 |
Integrated Biopharma's gross margin of this year was 0.09734479. Integrated Biopharma's gross margin of last year was 0.06623644.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Dec23) |
= | 52.124 | / | 25.721 | |
= | 2.0265153 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Dec22) |
= | 50.516 | / | 26.052 | |
= | 1.93904499 |
Integrated Biopharma's asset turnover of this year was 2.0265153. Integrated Biopharma's asset turnover of last year was 1.93904499.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 1 | + | 1 | + | 1 | + | 1 | + | 1 | + | 1 | + | 0 | + | 1 | + | 1 | |
= | 8 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Integrated Biopharma has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
Integrated Biopharma (OTCPK:INBP) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Integrated Biopharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Damon Desantis | director | 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431 |
William H. Milmoe | director, 10 percent owner | 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431 |
Joseph Laplaca | director | 72 EUGENE DRIVE, MONTVILLE NJ 07045 |
E Gerald Kay | director, 10 percent owner, officer: Chairman and CEO | C/O 225 LONG AVENUE, HILLSIDE NJ 07205 |
Bradley J Hoecker | director | STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Jeffrey R Leach | director, officer: President and CEO | |
Glenn Chang | director | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Vidadi Yusibov | director | C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Cd Financial, Llc | 10 percent owner | 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431 |
Kay Riva | director, officer: Vice President | C/O 225 LONG AVENUE, HILLSIDE NJ 07205 |
Christina Kay | director, officer: Vive President | C/O 225 LONG AVENUE, HILLSIDE NJ 07205 |
Robert Canarick | director | C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205 |
Robert Kay | director | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Dina Masi | officer: Chief Financial Officer | 14 LEXINGTON WAY, LONG VALLEY NJ 07853 |
Carl Desantis | director, 10 percent owner | C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 09-24-2020
By [email protected] [email protected] • 09-16-2019
By ACCESSWIRE ACCESSWIRE • 11-13-2020
By [email protected] [email protected] • 05-15-2019
By [email protected] [email protected] • 11-13-2019
By ACCESSWIRE AccessWire • 04-12-2019
By ACCESSWIRE AccessWire • 05-06-2019
By ACCESSWIRE ACCESSWIRE • 02-12-2021
By ACCESSWIRE ACCESSWIRE • 11-11-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.